EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy

Joshua Hurwitz iD, Lucy Roxana Haggstrom iD, Elgene Lim iD

Pharmaceutics · 26.07.2023 · 15 (8) · 2017

DOI: 10.3390/pharmaceutics15082017 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 26.07.2023. Verfasst von Joshua Hurwitz und 2 weiteren Autor:innen. Beteiligte Einrichtung: St. Vincent's Clinical School, Faculty of Medicine and Health, University of New South Wales, Kensington, NSW 2053, Australia. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Breast Cancer Endowed Chair, Love Your Sister.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugates (ADCs) have provided new therapeutic options and significant promise for patients with cancer, particularly where existing treatments are limited. Substantial effort in ADC development is underway globally, with 13 ADCs currently approved and many more in development. The therapeutic benefits of ADCs leverage the ability to selectively target cancer cells through antibody binding, resultant relative sparing of non-malignant tissues, and the targeted delivery of a cytotoxic payload. Consequently, this drug class has demonstrated activity in multiple malignancies refractory to standard therapeutic options. Despite this, limitations exist, including narrow therapeutic windows, unique toxicity profiles, development of therapeutic resistance, and appropriate biomarker selection. This review will describe the development of ADCs, their mechanisms of action, pivotal trials, and approved indications and identify common themes. Current challenges and opportunities will be discussed for this drug class in cancer therapeutics at a time when significant developments in antibody therapies, immunotherapy, and targeted agents are occurring.

Schlagwörter

Stichwörter der Autor:innen

antibody–drug conjugatecancerclinical trials

Autor:innen und Institutionen

  • St. Vincent's Clinical School, Faculty of Medicine and Health, University of New South Wales, Kensington, NSW 2053, Australia.
  • Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
  • Prince of Wales Hospital, Randwick, NSW 2031, Australia.

ORCID-Profile: Joshua Hurwitz, Lucy Roxana Haggstrom, Elgene Lim

Förderung

  • National Breast Cancer Endowed Chair
  • Love Your Sister

Zitieren

APA

Hurwitz, J., Haggstrom, L. R., & Lim, E. (2023). Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy. Pharmaceutics, 15(8), 2017. https://doi.org/10.3390/pharmaceutics15082017

Vancouver

Hurwitz J, Haggstrom LR, Lim E. Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy. Pharmaceutics. 2023;15(8):2017. doi:10.3390/pharmaceutics15082017

BibTeX
@article{Hurwitz2023,
  author = {Hurwitz, Joshua and Haggstrom, Lucy Roxana and Lim, Elgene},
  title = {Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {8},
  pages = {2017},
  doi = {10.3390/pharmaceutics15082017}
}
Kostenlos starten →